{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li W"],"funding":["Maternal and Child Health Hospital of Hubei Province Research Project"],"pagination":["e074245"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10533713"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(9)"],"pubmed_abstract":["<h4>Objective</h4>The objective of this study was to evaluate the comparative cost-effectiveness of lenvatinib (LEN) plus transarterial chemoembolisation (TACE) (LEN-TACE) and LEN alone to treat advanced hepatocellular carcinoma (HCC) from the perspective of the Chinese healthcare system.<h4>Design</h4>A three-state partitioned survival model using clinical survival data from a phase III LAUNCH trial, a 5-year time horizon for costs and quality-adjusted life years (QALYs) was constructed to analyse the cost-effectiveness of LEN-TACE. Clinical inputs were extracted from the LAUNCH trial, with outcomes extrapolated using standard and flexible parametric survival models. Costs and utilities derived from published literature were discounted at an annual rate of 5%. Sensitivity analyses and sce"],"journal":["BMJ open"],"pubmed_title":["Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China."],"pmcid":["PMC10533713"],"funding_grant_id":["2021SFYM030"],"pubmed_authors":["Li W","Wan L"],"additional_accession":[]},"is_claimable":false,"name":"Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.","description":"<h4>Objective</h4>The objective of this study was to evaluate the comparative cost-effectiveness of lenvatinib (LEN) plus transarterial chemoembolisation (TACE) (LEN-TACE) and LEN alone to treat advanced hepatocellular carcinoma (HCC) from the perspective of the Chinese healthcare system.<h4>Design</h4>A three-state partitioned survival model using clinical survival data from a phase III LAUNCH trial, a 5-year time horizon for costs and quality-adjusted life years (QALYs) was constructed to analyse the cost-effectiveness of LEN-TACE. Clinical inputs were extracted from the LAUNCH trial, with outcomes extrapolated using standard and flexible parametric survival models. Costs and utilities derived from published literature were discounted at an annual rate of 5%. Sensitivity analyses and sce","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2026-05-28T12:09:26.252Z","creation":"2025-05-18T11:55:32.889Z"},"accession":"S-EPMC10533713","cross_references":{"pubmed":["37751954"],"doi":["10.1136/bmjopen-2023-074245"]}}